Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results

@article{Schoffelen2013DevelopmentOA,
  title={Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results},
  author={Rafke Schoffelen and O. C. Boerman and David M. Goldenberg and Robert M Sharkey and C M L van Herpen and Gerben M. Franssen and William J. Mcbride and C.-H. Chang and Edmund A. Rossi and Winette T.A. van der Graaf and Wim J. G. Oyen},
  journal={British Journal of Cancer},
  year={2013},
  volume={109},
  pages={934 - 942}
}
Background:Radiolabelled antibody targeting of cancer is limited by slow blood clearance. Pretargeting with a non-radiolabelled bispecific monoclonal antibody (bsMAb) followed by a rapidly clearing radiolabelled hapten peptide improves tumour localisation. The primary goals of this first pretargeting study in patients with the anti-CEACAM5 × anti-hapten (HSG) bsMAb, TF2, and the radiolabelled hapten-peptide, IMP288, were to assess optimal pretargeting conditions and safety in patients with… 
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer
TLDR
These results show that individual high activity doses in PRIT in patients with CEA-expressing CRC could be safely administered by predicting the radiation dose to red marrow and kidneys, based on dosimetric analysis of a test dose of TF2 and 111In-IMP288.
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study
TLDR
This pilot study showed that pretargeted immuno-PET using anti-CEA/anti-IMP288 BsMAb and a [ 68 Ga]Ga-labelled hapten was safe and feasible, with promising diagnostic performance, and had an impact on management in 2 patients.
A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer
TLDR
A pretargeted approach for multimodal image-guided resection of colorectal cancer in a preclinical xenograft model is feasible, enables preoperative SPECT/CT, and might facilitate intraoperative fluorescence imaging.
Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT
TLDR
Improved tumor/organ ratios support the use of pretargeting method for imaging and therapy of CEA-expressing tumors and a strong correlation was demonstrated between tumor uptakes measured on PET images and biodistribution analyses.
Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
TLDR
The efficacy of pretargeted radioimmunotherapy with multiple cycles of TF12 and 177Lu-labeled diHSG-peptide (IMP288) in mice with s.c. PC3 tumors was investigated and the efficacy and toxicity of conventional RIT with 177LU-hRS7 dosed at the maximum tolerated dose was investigated.
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
TLDR
Investigating the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)–negative, carcinoembryonic antigen (CEA)–positive metastatic breast cancer, compared with CT, bone MRI, and 18F-FDG PET found it potentially sensitive theranostic imaging method for HER2-negative, CEA-positive breast cancer patients and warrants further research.
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
TLDR
This review focuses on MTC as an example, but the same pretargeting technique has been applied with success for clinical PET imaging of other CEA-expressing tumors and otherpretargeting systems.
New insights into the pretargeting approach to image and treat tumours.
TLDR
This tutorial review descriptively presents this complex strategy, addresses the historical as well as recent preclinical and clinical advances and discusses the advantages and disadvantages of different available variations.
Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent
TLDR
The use of a fluorescent-labeled anti-CEA antibody was safe and feasible for the intraoperative detection of both primary PDAC and metastases and warrant further research to determine the impact of this technique on clinical decision making and overall survival.
Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry
TLDR
The strategies and applications in (pre-)clinical studies of pretargeting concepts based on the use of bispecific antibodies, which are capable of binding to both a target antigen and a radiolabeled peptide, suggest that this chemicalpretargeting approach is an attractive alternative strategy for the detection and treatment of tumors.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts
TLDR
Pretargeted immuno-PET does exceptionally well with short-lived radionuclides and is a highly sensitive procedure that is more specific than 18F-FDG-PET.
Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colonic Tumors in Mice
TLDR
PRIT in mice is an effective treatment modality against colon cancer, with limited toxicity, and the optimization, therapeutic efficacy, and toxicity of PRIT of colon cancer with a 177Lu-labeled peptide was determined.
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
TLDR
The therapeutic responses observed in patients mainly with a small tumor burden are encouraging for the performance of a Phase I/II trial with minimal residual disease.
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
  • J. Chatal, L. Campion, +8 authors J. Barbet
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
PURPOSE No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma (MTC). The efficacy of pretargeted radioimmunotherapy (pRAIT) with
Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
TLDR
Both bsMAbs maintained their integrity and dual binding specificity in vivo, but the hMN-14 x m734 bsMAb was cleared more rapidly from the blood, indicating that early imaging with (99m)Tc and (188)Re radionuclides to tumors, using a bispecific antibody in a two-step approach will be possible.
New Antibody Conjugates in Cancer Therapy
TLDR
The Dock-and-Lock platform technology has contributed to the design and the evaluation of complex antibody-cytokine and antibody-toxin conjugates, with encouraging data published for the trastuzumab-DM1 conjugate in a phase I clinical trial in HER2-positive breast cancer.
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.
TLDR
This minireview discusses the various strategies and advancements made since the concept of pretargeting was proposed in the mid-1980s, with emphasis on those comprising bispecific antibodies for cancer therapy, and critical aspects of thesepretargeting systems for achieving higher tumor:nontumor ratios are considered.
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
TLDR
Both the median OS and 5-year survival rates seem to be improved with adjuvant RAIT after complete LM resection in CRC, compared with historical and contemporaneous controls not receiving RAIT, which justifies further evaluation of this modality in a multicenter, randomized trial.
Pretargeted radioimmunotherapy of cancer: progress step by step.
TLDR
In bispecific antibody-based pretargeting strategies, the use of bivalent haptens improved the efficacy of the tumor targeting, and a 2-step pretargeted radioimmunotherapy strategy is now being tested in cancer patients.
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
TLDR
Results indicate an improved therapeutic index with pretargeted radioimmunotherapy (RAIT) using a DNL-constructed tri-Fab, bsMAb, compared with conventional therapy with directly radiolabeled antibody or with a chemically conjugated bs MAb.
...
1
2
3
4
5
...